Novartis aims to nearly triple biosimilar drugs on market by 2020
June 19, 2016 at 18:01 PM EDT
KUFSTEIN, Austria, June 20 (Reuters) - Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals' profits.
